Steve Hibbert

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Dilan Athauda, Kate Maclagan, Simon S. Skene et al. · The Lancet · 2017 · 851 citations · Full text

Medicine, Neurology, Pharmacology +12

Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk

Elaine Chow, Alan Bernjak, S. Williams et al. · Diabetes · 2014 · 404 citations · Full text

Medicine, Cardiology, Internal Medicine +17

Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial

Stuart A. Taylor, Susan Mallett, Gauraang Bhatnagar et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 260 citations · Full text

Medicine, Clinical Sciences, Radiology +17

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Nirosen Vijiaratnam, Christine Girges, Grace Auld et al. · The Lancet · 2025 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

Nirosen Vijiaratnam, Christine Girges, Grace Auld et al. · BMJ Open · 2021 · 82 citations · Full text

Medicine, Neurology, Pharmacology +16